Longer and better lives for patients with atrial fibrillation: the 9th AFNET/EHRA consensus conference DOI Creative Commons
Dominik Linz, Jason G. Andrade, Elena Arbelo

et al.

EP Europace, Journal Year: 2024, Volume and Issue: 26(4)

Published: March 22, 2024

Abstract Aims Recent trial data demonstrate beneficial effects of active rhythm management in patients with atrial fibrillation (AF) and support the concept that a low arrhythmia burden is associated risk AF-related complications. The aim this document to summarize key outcomes 9th AFNET/EHRA Consensus Conference Atrial Fibrillation NETwork (AFNET) European Heart Rhythm Association (EHRA). Methods results Eighty-three international experts met Münster for 2 days September 2023. Key findings are as follows: (i) Active should be part default initial treatment all suitable AF. (ii) Patients device-detected AF have stroke. Anticoagulation prevents some strokes also increases major but non-lethal bleeding. (iii) More research needed improve stroke prediction AF, especially those burden. Biomolecules, genetics, imaging can this. (iv) presence trigger systematic workup comprehensive concomitant cardiovascular conditions. (v) Machine learning algorithms been used detection or likely development Cooperation between clinicians scientists leverage potential science applications Conclusions lower other events than high Combining control, anticoagulation, rate therapy conditions lives

Language: Английский

Congestion in heart failure: a circulating biomarker‐based perspective. A review from the Biomarkers Working Group of the Heart Failure Association, European Society of Cardiology DOI
Julio Núñez, Rafael de la Espriella, Patrick Rossignol

et al.

European Journal of Heart Failure, Journal Year: 2022, Volume and Issue: 24(10), P. 1751 - 1766

Published: Aug. 30, 2022

Language: Английский

Citations

93
Renal effects of guideline‐directed medical therapies in heart failure: a consensus document from the Heart Failure Association of the European Society of Cardiology DOI Open Access
Wilfried Müllens, Pieter Martens, Jeffrey M. Testani

et al.

European Journal of Heart Failure, Journal Year: 2022, Volume and Issue: 24(4), P. 603 - 619

Published: March 3, 2022

Language: Английский

Citations

92
Practical algorithms for early diagnosis of heart failure and heart stress using NT‐proBNP: A clinical consensus statement from the Heart Failure Association of the ESC DOI Open Access
Antoni Bayés‐Genís, Kieran F. Docherty, Mark C. Petrie

et al.

European Journal of Heart Failure, Journal Year: 2023, Volume and Issue: 25(11), P. 1891 - 1898

Published: Sept. 15, 2023

Language: Английский

Citations

87
Tricuspid Valve Academic Research Consortium Definitions for Tricuspid Regurgitation and Trial Endpoints DOI Creative Commons
Rebecca T. Hahn, Matthew Lawlor,

Charles J. Davidson

et al.

Journal of the American College of Cardiology, Journal Year: 2023, Volume and Issue: 82(17), P. 1711 - 1735

Published: Oct. 1, 2023

Interest in the pathophysiology, etiology, management, and outcomes of patients with tricuspid regurgitation (TR) has grown wake multiple natural history studies showing progressively worse associated increasing TR severity, even after adjusting for comorbidities. Historically, isolated valve surgery been high in-hospital mortality rates, leading to development transcatheter treatment options. The aim this first Tricuspid Valve Academic Research Consortium document is standardize definitions disease etiology as well endpoints trials that address gaps our knowledge related identification management TR. Standardizing should provide consistency enable meaningful comparisons between clinical trials. A second will focus on further defining trial discuss design

Language: Английский

Citations

84
Patient phenotype profiling in heart failure with preserved ejection fraction to guide therapeutic decision making. A scientific statement of the Heart Failure Association, the European Heart Rhythm Association of the European Society of Cardiology, and the European Society of Hypertension DOI Creative Commons
Stefan D. Anker, Muhammad Usman, Markus S. Anker

et al.

European Journal of Heart Failure, Journal Year: 2023, Volume and Issue: 25(7), P. 936 - 955

Published: May 19, 2023

Abstract Heart failure with preserved ejection fraction (HFpEF) represents a highly heterogeneous clinical syndrome affected in its development and progression by many comorbidities. The left ventricular diastolic dysfunction may be manifestation of various combinations cardiovascular, metabolic, pulmonary, renal, geriatric conditions. Thus, addition to treatment sodium–glucose cotransporter 2 inhibitors all patients, the most effective method improving outcomes therapy tailored each patient's profile. To better outline phenotype‐based approach for HFpEF, this joint position paper, Failure Association European Society Cardiology, Rhythm Hypertension Society, have developed an algorithm identify common HFpEF phenotypes evidence‐based strategy each, while taking into account complexities multiple comorbidities polypharmacy.

Language: Английский

Citations

79
Intravenous iron in patients with heart failure and iron deficiency: an updated meta‐analysis DOI Creative Commons
Fraser J Graham, Pierpaolo Pellicori, Paul R. Kalra

et al.

European Journal of Heart Failure, Journal Year: 2023, Volume and Issue: 25(4), P. 528 - 537

Published: Feb. 24, 2023

Abstract Aims For patients with heart failure (HF) and iron deficiency (ID), randomized trials suggest that intravenous (IV) reduces hospitalizations for (HHF), but uncertainty exists about the effects in subgroups impact on mortality. We conducted a meta‐analysis of investigating effect IV clinical outcomes HF. Methods results identified published between 1 January 2000 5 November 2022 versus standard care/placebo HF ID any setting, regardless phenotype. Trials oral or not English were included. The main interest composite HHF cardiovascular death (CVD), alone all‐cause Ten 3373 participants, whom 1759 assigned to iron. reduced recurrent CVD (rate ratio 0.75, 95% confidence interval [CI] 0.61–0.93; p < 0.01) first (odds [OR] 0.72, CI 0.53–0.99; = 0.04). Effects (OR 0.86, 0.70–1.05; 0.14) mortality 0.93, 0.78–1.12; 0.47) inconclusive. Results similar analyses confined year follow‐up, which was less disrupted by COVID‐19 pandemic. Subgroup found little evidence heterogeneity primary endpoint, although transferrin saturation <20% 0.67, 0.49–0.92) may have benefited more than those values ≥20% 0.99, 0.74–1.30) (heterogeneity 0.07). Conclusion In ID, this suggests risk whether is associated reduction remains

Language: Английский

Citations

78
Mitral valve transcatheter edge-to-edge repair DOI Open Access

Jörg Hausleiter,

Thomas J. Stocker, Marianna Adamo

et al.

EuroIntervention, Journal Year: 2023, Volume and Issue: 18(12), P. 957 - 976

Published: Jan. 1, 2023

Mitral regurgitation (MR) is the most prevalent valvular heart disease and, when left untreated, results in reduced quality of life, failure, and increased mortality. valve transcatheter edge-to-edge repair (M-TEER) has matured considerably as a non-surgical treatment option since its commercial introduction Europe 2008. As result major device interventional improvements, well accumulation experience by cardiologists, M-TEER emerged an important therapeutic strategy for patients with severe symptomatic MR current European American guidelines. Herein, we provide comprehensive up-do-date overview M-TEER. We define preprocedural patient evaluation highlight key aspects decision-making. describe currently available systems summarise evidence both primary mitral (PMR) secondary (SMR). In addition, recommendations selection, intraprocedural imaging guiding, optimisation management recurrent MR. Finally, information on unsolved questions “grey areas”

Language: Английский

Citations

71
Left Bundle Branch Area Pacing Versus Biventricular Pacing as Initial Strategy for Cardiac Resynchronization DOI Creative Commons
Juan Carlos Díaz, William H. Sauer, Mauricio Duque

et al.

JACC. Clinical electrophysiology, Journal Year: 2023, Volume and Issue: 9(8), P. 1568 - 1581

Published: May 21, 2023

Language: Английский

Citations

66
Global epidemiology of heart failure DOI
Muhammad Shahzeb Khan, Izza Shahid, Ahmed Bennis

et al.

Nature Reviews Cardiology, Journal Year: 2024, Volume and Issue: 21(10), P. 717 - 734

Published: June 26, 2024

Language: Английский

Citations

57
The traditional Chinese medicines treat chronic heart failure and their main bioactive constituents and mechanisms DOI Creative Commons
Jie Chen,

Xiao‐Hong Wei,

Qian Zhang

et al.

Acta Pharmaceutica Sinica B, Journal Year: 2023, Volume and Issue: 13(5), P. 1919 - 1955

Published: Feb. 11, 2023

Chronic heart failure (CHF) is a severe public health problem with increasing morbidity and mortality, any treatment targeting single session insufficient to tackle this. CHF characterized by reduced cardiac output resulting from neurohumoral dysregulation remodeling, which might be related oxidative stress, inflammation, endoplasmic reticulum apoptosis, autophagy, mitochondrial function, angiogenesis. These molecular mechanisms interact each other through crosstalk. Historically, Chinese medicinal herbs have been widely applied in the of CHF, therapeutic effects their ingredients scientifically confirmed over past decades. Traditional medicine (TCM) multiple components can confront different pathogenesis targets. This review analyzes commonly used TCM patent drugs decoctions that are applicable stages based on clinical trials. Diverse bioactive found treat via mechanisms. comprehensively covers key works underlying TCM, herbal synergistic constituent compatibility treating providing additional ideas address this threat.

Language: Английский

Citations

53